Efficacy of antiandrogens in androgen receptor-positive triple-negative metastatic breast cancer: Real-life data

Breast. 2024 Feb:73:103667. doi: 10.1016/j.breast.2023.103667. Epub 2023 Dec 22.

Abstract

Antiandrogens (AA) have been tested in clinical trials in androgen receptor (AR) + triple-negative breast cancer (TNBC). We aim to assess the clinical benefit rate (CBR) of AA in real life. The primary end-point was CBR at 6 months. Twenty-four patients were assessable and received: abiraterone acetate (62 %), enzalutamide (8 %) and bicalutamide (30 %). CBR at 6 months was 29 % (7/24) with 2 CR, 3 PR and 2 SD. Four patients had a clinical benefit >12 months. Real-life efficacy of AA use in metastatic AR + TNBC are in line with data from published trials.

Keywords: Androgen receptor; Androgen receptor-positive triple-negative breast cancer; Antiandrogens; Biomarker; Clinical benefit rate; Real-life data.

MeSH terms

  • Androgen Antagonists* / therapeutic use
  • Humans
  • Nitriles / therapeutic use
  • Receptors, Androgen
  • Triple Negative Breast Neoplasms* / drug therapy
  • Triple Negative Breast Neoplasms* / pathology

Substances

  • Androgen Antagonists
  • Receptors, Androgen
  • Nitriles